CRISPR Therapeutics stock heads to Jefferies conference on November 17
Published on 11/11/2026 at 03:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSConference plans and pipeline focus
- CRISPR Therapeutics plans a management presentation at an upcoming healthcare investor conference.
- The company is advancing gene-based medicines, including clinical work on CTX310 and zugo-cel.
- Its pipeline spans severe genetic, metabolic, autoimmune and cancer-related diseases.
CRISPR Therapeutics announced on Tuesday, November 10, 2026, that members of its senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17. The company said the session will begin at 10:00 a.m. GMT and will be webcast through its investor-relations website. The announcement was carried by CRISPR Therapeutics.
CRISPR Therapeutics stock traded at 40.83 euros on Lang & Schwarz at 23:00 CET on Tuesday, November 10, 2026. The quote carried a change of 0.03 euros, or 0.07 percent, against the previous Lang & Schwarz close.
Investor focus turns to pipeline updates
The conference appearance gives investors a scheduled opportunity to hear from management as the company advances its clinical pipeline. The investor-relations page lists recent activity around CTX310, a program targeting ANGPTL3 and triglycerides, and zugo-cel in refractory rheumatologic autoimmune diseases.
CRISPR Therapeutics also said it would present clinical data from zugo-cel in large B-cell lymphoma at the 68th American Society of Hematology Annual Meeting. The sequence of presentations keeps clinical data and development progress at the center of the company's investor narrative.
Gene medicines define the business
CRISPR Therapeutics develops gene-based medicines for serious diseases, using CRISPR gene-editing technology across programs in blood disorders, metabolic disease, autoimmune conditions and cancer. The company is headquartered in Zug, Switzerland, and also has operations in Boston, United States. Its specialization places it in the same gene-editing field as Intellia Therapeutics, Editas Medicine and Beam Therapeutics, with CRISPR Therapeutics focused on advancing CRISPR-based therapies across several disease areas.
CRISPR Therapeutics at a glance
- Company: CRISPR Therapeutics AG
- ISIN: CH0334081137
- Ticker: CRSP
- Trading venue: Lang & Schwarz
- Price: 40.83 euros at 23:00 CET on November 10, 2026
- Change: 0.03 euros, or 0.07 percent, against the previous Lang & Schwarz close
- Headquarters: Zug, Switzerland
US biotechnology shares remain sensitive to clinical updates, regulatory milestones and investor-conference commentary. For broader market developments, see current S&P 500 market reports.
More news and analyses on CRISPR Therapeutics stock.
